PR95634

DUBLIN, April 26, 2022 /PRNewswire=KYODO JBN/ --

ERS Genomics Limited ("ERS") is pleased to confirm finalization of a license

agreement with Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") granting Sumitomo

Pharma non-exclusive access to the fundamental CRISPR/Cas9 intellectual

property portfolio held by ERS.

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for

gene-editing, provides access to the foundational CRISPR/Cas9 intellectual

property. Eighty-nine patents are held in over eighty countries, including 3

patents in Japan with broad coverage of the use of CRISPR/Cas9.

ERS CEO Eric Rhodes had the following statement: "We have been working with

Sumitomo Pharma's group for some time and are pleased to finally be able to

announce this agreement. Sumitomo Pharma has a reputation worldwide for

excellence and vision, and we look forward to seeing how CRISPR/Cas9 will

enhance their internal research programs and lead to more effective drugs."

Expanding on the regional aspect of the deal, Eric added: "Japan has one of the

most developed biotechnology sectors in the world and we hope this partnership

with Sumitomo Pharma is a signifier of a growing presence in this country. This

represents ERS's 16th license deal in Japan."

Financial details of the agreement are not disclosed.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo

Corporation, serves as the exclusive agent for ERS Genomics in Japan.

About ERS Genomics

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company

was formed to provide broad access to the foundational CRISPR/Cas9 intellectual

property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are

available for research and sale of products and services across multiple fields

including: research tools, kits, reagents; discovery of novel targets for

therapeutic intervention; cell lines for discovery and screening of novel drug

candidates; GMP production of healthcare products; companion animal and

livestock health; production of industrial materials such as enzymes, biofuels

and chemicals; and synthetic biology.

For additional information, please visit www.ersgenomics.com .

Photo - https://mma.prnewswire.com/media/1803591/ERS_Genomics_Eric_Rhodes.jpg

Logo - https://mma.prnewswire.com/media/1756881/ERS_Genomics_Logo.jpg

Media contact:

Dara O'Donnell

dara.odonnell@ersgenomics.com

+353-1-539 0083

ERS contact:

Yasuto Ando

alliance@summitpharma.co.jp

Source: ERS Genomics